Treatment Options
249 articles
PanCAN 2021 Annual Scientific Summit
Pancreatic Cancer Action Network (PanCAN) held its annual scientific summit for an overview of the latest research projects they are funding.
Disappointing Results of a Phase II Trial Using Angiogenesis Inhibitor
Dr. Tanios Bekaii-Saab reports on the disappointing results of a trial combining an angiogenesis inhibitor and mFOLFIRINOX.
Pancreatic Cancer Patients in the UK Benefit From Unique Precision Medicine Project
Dr. David Chang explains the Precision Panc initiative, a program through the UK’s NHS that helps pancreatic cancer patients find treatments.
Challenge Grant Recipients Moving Forward
The Pancreatic Cancer Collective awarded four teams a second round of New Therapies Challenge Grants, to further develop new pancreatic cancer treatment.
Chemo and SBRT for Inoperable Pancreatic Cancer
For inoperable pancreatic cancer, researchers are comparing mFOLFIRINOX and SBRT with gemcitabine-based treatment regimens.
Novel Oral Drug Shows Promise
Dr. Barbara Ma provides context for the nine-month data on a clinical trial of the novel drug atebimetinib and standard chemo.
KRYSTAL-1 Trial Shows Promising Activity in Pancreas and Other GI Cancers
Dr. Tanios Bekaii-Saab reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer.
Triple Immunotherapy Shows Dramatic Results
Dr. William Freed-Pastor is testing a combination of three types of immunotherapy to attack pancreatic tumors.
Positive Results For Borderline Resectable Disease Pilot Study
Dr. Zev Wainberg provides details on a trial of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer.
Phase II/III Clinical Trial Recruiting Advanced Pancreatic Cancer Patients
Dr. Shalini Makawita is a primary investigator in a phase IIb/III immunotherapy clinical trial for advanced pancreatic cancer patients.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
The Promise of Organoids
Dr. Brian Wolpin explains how organoids are being used to develop personalized treatment for pancreatic cancer patients.
Targeting Mutant KRAS with Immunotherapy
Dr. Beatriz Carreno explains how her team is targeting the KRAS mutation with a pancreatic cancer vaccine to make the immune system work against cancer.
Platform Trial Design Aims to Get Information Quickly and Efficiently
Dr. Eugene Koay is leading a platform trial, for a more nimble way to adapt to participants’ response to treatments being tested.